Jans S W, de Jong Y F, Reutelingsperger C P, van der Vusse G J, van Bilsen M
Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands.
Mol Cell Biochem. 1998 Jan;178(1-2):229-36. doi: 10.1023/a:1006803900554.
Recently it was shown that annexin V is the most prominent member of the annexin family in the adult heart [1]. Amongst others, annexin V has been suggested to play a role in developmental processes. The aim of the present study was to explore whether in the heart annexin V content and localization change during maturational and hypertrophic growth, in order to obtain indications that annexin V is involved in cardiac growth processes. First, in the intact rat heart annexin V content and localization were studied during perinatal development. It was clearly demonstrated that annexin V content in total heart transiently increased in the first week after birth, from 0.79 +/- 0.06 microg/mg protein at 1 day before birth to a peak value of 1.24 +/- 0.08 microg/mg protein 6 days after birth, whereafter annexin V protein levels declined to a value of 0.70 +/- 0.06 microg/mg protein at 84 days after birth (p < 0.05). Differences in annexin V content were also observed between myocytes isolated from neonatal and adult hearts [0.81 +/- 0.09 and 0.17 +/- 0.08 microg/mg protein, respectively (p < 0.05)]. Moreover, during cardiac maturational growth the subcellular localization of annexin V might change from a cytoplasmic to a more prominent sarcolemmal localization. Second, in vivo hypertrophy induced by aortic coarctation resulted in a marked degree of hypertrophy (22% increase in ventricular weight), but was not associated with a change in annexin V localization or content. The quantitative results obtained with intact hypertrophic rat hearts are supported by findings in neonatal ventricular myocytes, in which hypertrophy was induced by phenylephrine (10(-5) M). In the latter model no changes in annexin V content could be observed either. In conclusion, the marked alterations in annexin V content during the maturational growth in the heart suggest a possible involvement of this protein in this process. In contrast, the absence of changes in annexin V content and localization in hypertrophied hearts compared to age matched control hearts suggests that annexin V does not play a crucial role in the maintenance of the hypertrophic phenotype of the cardiac muscle cell. This notion is supported by observations in phenylephrine-induced hypertrophied neonatal cardiomyocytes.
最近研究表明,膜联蛋白V是成年心脏中膜联蛋白家族最主要的成员[1]。除此之外,膜联蛋白V被认为在发育过程中发挥作用。本研究的目的是探究在心脏成熟和肥大生长过程中膜联蛋白V的含量及定位是否发生变化,以便获得膜联蛋白V参与心脏生长过程的迹象。首先,在完整的大鼠心脏中研究围产期发育过程中膜联蛋白V的含量及定位。结果清楚地表明,出生后第一周,全心脏中膜联蛋白V的含量短暂增加,从出生前1天的0.79±0.06微克/毫克蛋白增加到出生后6天的峰值1.24±0.08微克/毫克蛋白,此后膜联蛋白V的蛋白水平下降,在出生后84天降至0.70±0.06微克/毫克蛋白(p<0.05)。从新生心脏和成年心脏分离的心肌细胞中也观察到膜联蛋白V含量的差异[分别为0.81±0.09和0.17±0.08微克/毫克蛋白(p<0.05)]。此外,在心脏成熟生长过程中,膜联蛋白V的亚细胞定位可能从细胞质转变为更显著的肌膜定位。其次,主动脉缩窄诱导的体内肥大导致显著程度的肥大(心室重量增加22%),但与膜联蛋白V的定位或含量变化无关。完整肥大大鼠心脏获得的定量结果得到新生心室肌细胞研究结果的支持,在新生心室肌细胞中,苯肾上腺素(10⁻⁵M)诱导肥大。在后一种模型中,也未观察到膜联蛋白V含量的变化。总之,心脏成熟生长过程中膜联蛋白V含量的显著变化表明该蛋白可能参与此过程。相反,与年龄匹配的对照心脏相比,肥大心脏中膜联蛋白V含量和定位没有变化,这表明膜联蛋白V在维持心肌细胞肥大表型方面不发挥关键作用。苯肾上腺素诱导肥大的新生心肌细胞中的观察结果支持了这一观点。